Phase 2 Trial of AT-1501 in Slowing Progression Nears Full Enrollment

Phase 2 Trial of AT-1501 in Slowing Progression Nears Full Enrollment

304276

Phase 2 Trial of AT-1501 in Slowing Progression Nears Full Enrollment

Eledon Pharmaceuticals announced that its Phase 2 study of AT-1501 in people with amyotrophic lateral sclerosis (ALS) should be fully enrolled by year’s end. Top-line trial results are expected between April and September 2022. “Enrollment in our ALS study is progressing well and we anticipate completing enrollment in the 4th quarter,” David-Alexandre C. Gros, MD, CEO of Eledon, said in a press release. The trial (NCT04322149), which enrolled its first patient late last year, is recruiting…

You must be logged in to read/download the full post.